Prokidney (PROK) Cash from Financing Activities (2021 - 2026)
Prokidney (PROK) reported Cash from Financing Activities of $215000.0 for Q1 2026, up 1891.67% year-over-year from $10795.0 in Q1 2025, and down 98.78% on a QoQ basis from $17.6 million in Q4 2025.
Prokidney (PROK) has 6 years of Cash from Financing Activities data on file, last reported at $215000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 1891.67% year-over-year to $215000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (down 82.14% YoY) and the FY2025 annual result came in at $25.6 million, down 82.29% from the prior year.
- Cash from Financing Activities eased to $215000.0 in Q1 2026 per PROK's latest filing, from $17.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $507.5 million in Q3 2022 and bottomed at -$9.5 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is $123000.0 (2024), against an average of $41.7 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities jumped 18508595.65%; it then slumped 118800.0% in 2023.
- Tracing PROK's Cash from Financing Activities over 5 years: stood at -$8000.0 in 2022, then tumbled by 118800.0% to -$9.5 million in 2023, then soared by 101.29% to $123000.0 in 2024, then surged by 14236.59% to $17.6 million in 2025, then slumped by 98.78% to $215000.0 in 2026.
- Per Business Quant, the three latest PROK Cash from Financing Activities figures stand at $215000.0 (Q1 2026), $17.6 million (Q4 2025), and $8.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Prokidney | 259.72 Mn | 1.55 Bn | - | 215,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215,000.00 |
| Mar 31, 2026 | 215,000.00 |
| Dec 31, 2025 | 17.63 Mn |
| Dec 31, 2025 | 17.63 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | -14,000.00 |
| Jun 30, 2025 | -14,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 4.46 Mn |
| Sep 30, 2024 | 4.46 Mn |
| Jun 30, 2024 | 139.84 Mn |
| Jun 30, 2024 | 139.84 Mn |
| Mar 31, 2024 | -13,000.00 |
| Mar 31, 2024 | -13,000.00 |
| Dec 31, 2023 | -9.51 Mn |
| Dec 31, 2023 | -9.51 Mn |
| Sep 30, 2023 | -13,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Mar 31, 2023 | -13,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | 507.50 Mn |
| Sep 30, 2022 | 507.50 Mn |
| Jun 30, 2022 | 15.49 Mn |
| Jun 30, 2022 | 15.49 Mn |
| Mar 31, 2022 | 25.54 Mn |
| Mar 31, 2022 | 25.54 Mn |
| Dec 31, 2021 | 251.65 Mn |
| Dec 31, 2021 | 251.65 Mn |
| Sep 30, 2021 | 251.68 Mn |
| Sep 30, 2021 | 251.68 Mn |
| Jun 30, 2021 | 243,375.00 |
| Jun 30, 2021 | 243,375.00 |
| Mar 31, 2021 | 138.00 |
| Mar 31, 2021 | 138.00 |